Aberdeen Group plc Trims Stock Position in Boston Scientific Corporation $BSX

Key Points

• Aberdeen Group plc decreased its stake in Boston Scientific Corporation by 8.6%, selling 242,523 shares and owning approximately 0.18% of the company valued at $275.76 million.
• A significant number of hedge funds have adjusted their positions in Boston Scientific, with various firms reporting increases ranging from 1.4% to 13.9% in ownership during the recent quarters.
• Boston Scientific's stock recently traded at $95.41, with a reported 22.8% year-over-year increase in revenue for the last quarter, alongside earnings per share of $0.75.

Aberdeen Group plc reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,592,454 shares of the medical equipment provider's stock after selling 242,523 shares during the quarter. Aberdeen Group plc owned approximately 0.18% of Boston Scientific worth $275,759,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. HM Payson & Co. increased its position in Boston Scientific by 1.4% during the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after purchasing an additional 98 shares during the period. IVC Wealth Advisors LLC increased its position in Boston Scientific by 4.9% during the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider's stock valued at $236,000 after purchasing an additional 102 shares during the period. Park Square Financial Group LLC grew its position in shares of Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock worth $208,000 after buying an additional 103 shares during the period. HHM Wealth Advisors LLC grew its position in shares of Boston Scientific by 13.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock worth $89,000 after buying an additional 103 shares during the period. Finally, Rise Advisors LLC grew its position in shares of Boston Scientific by 13.9% in the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider's stock worth $85,000 after buying an additional 103 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $17,972,457 over the last quarter. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Shares of BSX stock opened at $95.41 on Friday. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The company's 50-day moving average is $101.98 and its 200 day moving average is $101.87. The company has a market capitalization of $141.38 billion, a price-to-earnings ratio of 56.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the firm posted $0.62 EPS. Boston Scientific's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BSX. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Boston Scientific in a research report on Wednesday. Needham & Company LLC reaffirmed a "buy" rating and issued a $121.00 target price on shares of Boston Scientific in a research report on Wednesday, October 1st. BTIG Research upped their target price on shares of Boston Scientific from $127.00 to $132.00 and gave the stock a "buy" rating in a research report on Wednesday, October 1st. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Finally, Truist Financial upped their target price on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a "buy" rating in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $120.71.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.